Digestive Diseases and Sciences

, Volume 56, Issue 1, pp 103–108 | Cite as

Influence of MDR1 Polymorphism on H. pylori-Related Chronic Gastritis

  • Tomomitsu Tahara
  • Tomoyuki Shibata
  • Hiromi Yamashita
  • Ichiro Hirata
  • Tomiyasu Arisawa
Original Article



There is evidence that changes in MDR1 function and/or expression contribute to the pathogenesis of inflammatory disorders of the gastrointestinal tract.


We aimed to investigate the effect of C3435T polymorphism of the MDR1 gene on histological chronic gastritis, and on the risk of peptic ulcer diseases.


Restriction fragment length polymorphism analysis was performed for polymorphisms at C3435T in the MDR1 gene in 556 cancer-free subjects including 116 gastric and 60 duodenal ulcers, and 380 non-ulcer subjects. Gastritis scores in the antrum were assessed according to the updated Sydney system in 384 subjects.


We did not find a significant association between MDR1 genotype and gastritis scores in any of the 384 subjects. However, the 3435T carrier was significantly associated with a higher degree of neutrophil infiltration in H. pylori-positive subjects (CC vs. T carrier: p = 0.0495). When the H. pylori positive subjects were divided according to generation, the 3435T carrier was significantly associated with a higher degree of neutrophil infiltration in subjects more than 65 years of age (CC vs. T carrier: p = 0.03). Also, the MDR1 3435 TT genotype was significantly associated with a higher degree of atrophy and intestinal metaplasia in the same generation (atrophy, TT vs. C carrier: p = 0.038, intestinal metaplasia, TT vs. C carrier: p = 0.016). No association was found between MDR1 genotypes and risk of peptic ulcer diseases.


It appears that the C3435T polymorphism of MDR1 influences H. pylori-related inflammatory conditions in the stomach, especially in older subjects.


Chronic gastritis MDR1 Polymorphism Stomach C3435T H. pylori 


H. pylori

Helicobacter pylori


Multidrug resistance 1


  1. 1.
    NIH Consensus Conference. Helicobacter pylori in peptic ulcer disease. NIH Consensus Development Panel on Helicobacter pylori in Peptic Ulcer disease. JAMA. 1994;272:65–69.CrossRefGoogle Scholar
  2. 2.
    Uemura N, Okamoto S, Yamamoto S, et al. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med. 2001;345:784–789.CrossRefPubMedGoogle Scholar
  3. 3.
    Parsonnet J, Friedman GD, Vandersteen DP, et al. Helicobacter pylori infection and the risk of gastric carcinoma. N Engl J Med. 1991;325:1127–1131.CrossRefPubMedGoogle Scholar
  4. 4.
    Huang JQ, Sridhar S, Chen Y, Hunt RH. Meta-analysis of the relationship between Helicobacter pylori seropositivity and gastric cancer. Gastroenterology. 1998;114:1169–1179.CrossRefPubMedGoogle Scholar
  5. 5.
    Blaser MJ, Parsonnet J. Parasitism by the “slow” bacterium Helicobacter pylori leads to altered gastric homeostasis and neoplasia. J Clin Invest. 1994;94:4–8.CrossRefPubMedGoogle Scholar
  6. 6.
    Higgins CF. ABC transporters: from microorganisms to man. Annu Rev Cell Biol. 1992;8:67–113.CrossRefPubMedGoogle Scholar
  7. 7.
    van Veen HW, Venema K, Bolhuis H, et al. Multidrug resistance mediated by a bacterial homolog of the human multidrug transporter MDR1. Proc Natl Acad Sci USA. 1996;93:10668–10672.CrossRefPubMedGoogle Scholar
  8. 8.
    van Veen HW, Konings WN. The ABC family of multidrug transporters in microorganisms. Biochim Biophys Acta. 1998;1365:31–36.CrossRefPubMedGoogle Scholar
  9. 9.
    Dean M, Rzhetsky A, Allikmets R. The human ATP-binding cassette (ABC) transporter superfamily. Genome Res. 2001;11:1156–1166.CrossRefPubMedGoogle Scholar
  10. 10.
    Ambudkar SV, Dey S, Hrycyna CA, Ramachandra M, Pastan I, Gottesman MM. Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu Rev Pharmacol Toxicol. 1999;39:361–398.CrossRefPubMedGoogle Scholar
  11. 11.
    Ho GT, Moodie FM, Satsangi J. Multidrug resistance 1 gene (P-glycoprotein170): an important determinant in gastrointestinal disease? Gut. 2003;52:759–766.CrossRefPubMedGoogle Scholar
  12. 12.
    Banner KH, Cattaneo C, Le Net JL, Popovic A, Collins D, Gale JD. Macroscopic, microscopic and biochemical characterisation of spontaneous colitis in a transgenic mouse, deficient in the multiple drug resistance 1a gene. Br J Pharmacol. 2004;143:590–598.CrossRefPubMedGoogle Scholar
  13. 13.
    Wilk JN, Bilsborough J, Viney JL. The mdr1a−/− mouse model of spontaneous colitis: a relevant and appropriate animal model to study inflammatory bowel disease. Immunol Res. 2005;31:151–160.CrossRefPubMedGoogle Scholar
  14. 14.
    Kalitsky-Szirtes J, Shayeqanpour A, Brocks DR, Piquette-Miller M. Suppression of drug-metabolizing enzymes and efflux transporters in the intestine of endotoxin-treated rats. Drug Metab Dispos. 2004;32:20–27.CrossRefPubMedGoogle Scholar
  15. 15.
    Buyse M, Radeva G, Bado A, Farinotti R. Intestinal inflammation induces adaptation of P-glycoprotein expression and activity. Biochem Pharmacol. 2005;69:1745–1754.CrossRefPubMedGoogle Scholar
  16. 16.
    Cascorbi I, Gerloff T, Johne A, et al. Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects. Clin Pharmacol Ther. 2001;69:169–174.CrossRefPubMedGoogle Scholar
  17. 17.
    Hoffmeyer S, Burk O, von Richter O, et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci U S A. 2000;97:3473–3478.CrossRefPubMedGoogle Scholar
  18. 18.
    Siegsmund M, Brinkmann U, Scháffeler E, et al. Association of the P-glycoprotein transporter MDR1(C3435T) polymorphism with the susceptibility to renal epithelial tumors. J Am Soc Nephrol. 2002;13:1847–1854.CrossRefPubMedGoogle Scholar
  19. 19.
    Schwab M, Schaeffeler E, Marx C, et al. Association between the C3435T MDR1 gene polymorphism and susceptibility for ulcerative colitis. Gastroenterology. 2003;124:26–33.CrossRefPubMedGoogle Scholar
  20. 20.
    Tahara T, Arisawa T, Shibata T, Hirata I, Nakano H. Multi-drug resistance 1 polymorphism is associated with reduced risk of gastric cancer in the Japanese population. J Gastroenterol Hepatol. 2007;22:1678–1682.CrossRefPubMedGoogle Scholar
  21. 21.
    Dixon MF, Genta RM, Yardley JH, Correa P. Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994. Am J Surg Pathol. 1996;20:1161–1181.CrossRefPubMedGoogle Scholar
  22. 22.
    Drozdzik M, Bialecka M, Mysliwiec K, Honczarenko K, Stankiewicz J, Sych Z. Polymorphism in the P-glycoprotein drug transporter MDR1 gene: a possible link between environmental and genetic factors in Parkinson’s disease. Pharmacogenetics. 2003;13:259–263.CrossRefPubMedGoogle Scholar
  23. 23.
    Correa P. Helicobacter pylori and gastric carcinogenesis. Am J Surg Pathol. 1995;19(Suppl 1):S37–S43.PubMedGoogle Scholar
  24. 24.
    El-Omar EM, Penman ID, Ardill JE, Chittajallu RS, Howie C, McColl KE. Helicobacter pylori infection and abnormalities of acid secretion in patients with duodenal ulcer disease. Gastroenterology. 1995;109:681–691.CrossRefPubMedGoogle Scholar
  25. 25.
    Lee S, Iida M, Yao T, et al. Risk of gastric cancer in patients with non-surgically treated peptic ulcer. Scand J Gastroenterol. 1990;25:1223–1226.CrossRefPubMedGoogle Scholar
  26. 26.
    Sugimoto M, Furuta T, Shirai N, et al. MDR1 C3435T polymorphism has no influence on developing Helicobacter pylori infection-related gastric cancer and peptic ulcer in Japanese. Life Sci. 2008;83:301–304.CrossRefPubMedGoogle Scholar
  27. 27.
    Kim RB, Leake BF, Choo EF, et al. Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin Pharmacol Ther. 2001;70:189–199.CrossRefPubMedGoogle Scholar
  28. 28.
    Fellay J, Marzolini C, Meaden ER, et al. Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study. Lancet. 2002;359:30–36.CrossRefPubMedGoogle Scholar
  29. 29.
    Hitzl M, Drescher S, van der Kuip H, et al. Fromm MF The C3435T mutation in the human MDR1 gene is associated with altered efflux of the P-glycoprotein substrate rhodamine 123 from CD56+ natural killer cells. Pharmacogenetics. 2001;11:293–298.CrossRefPubMedGoogle Scholar
  30. 30.
    Nakamura T, Sakaeda T, Horinouchi M, et al. Effect of the mutation (C3435T) at exon 26 of the MDR1 gene on expression level of MDR1 messenger ribonucleic acid in duodenal enterocytes of healthy Japanese subjects. Clin Pharmacol Ther. 2002;71:297–303.CrossRefPubMedGoogle Scholar
  31. 31.
    Nardone G, Rocco A, Vaira D, et al. Expression of COX-2, mPGE-synthase1, MDR-1 (P-gp), and Bcl-xL: a molecular pathway of H pylori-related gastric carcinogenesis. J Pathol. 2004;202(3):305–312.CrossRefPubMedGoogle Scholar
  32. 32.
    Ameyaw MM, Regateiro F, Li T, et al. MDR1 pharmacogenetics: frequency of the C3435T mutation in exon 26 is significantly influenced by ethnicity. Pharmacogenetics. 2001;11:217–221.CrossRefPubMedGoogle Scholar
  33. 33.
    Sakaeda T, Nakamura T, Horinouchi M, et al. MDR1 genotype-related pharmacokinetics of digoxin after single oral administration in healthy Japanese subjects. Pharm Res. 2001;18:1400–1404.CrossRefPubMedGoogle Scholar
  34. 34.
    Bernal ML, Sinues B, Fanlo A, Mayayo E. Frequency distribution of C3435T mutation in exon 26 of the MDR1 gene in a Spanish population. Ther Drug Monit. 2003;25:107–111.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  • Tomomitsu Tahara
    • 1
  • Tomoyuki Shibata
    • 1
  • Hiromi Yamashita
    • 1
  • Ichiro Hirata
    • 1
  • Tomiyasu Arisawa
    • 2
  1. 1.Department of GastroenterologyFujita Health University School of MedicineToyoakeJapan
  2. 2.Department of GastroenterologyKanazawa Medical UniversityUchinadamachiJapan

Personalised recommendations